Ozempic

Product manufactured by Novo Nordisk

Application Nr Approved Date Route Status External Links
NDA209637 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Ozempic Is Indicated: • As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus [See Clinical Studies ( 14.1 )] . • To Reduce The Risk Of Major Adverse Cardiovascular Events ( Cardiovascular Death, Non-Fatal Myocardial Infarction Or Non-Fatal Stroke) In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease [See Clinical Studies ( 14.4 )]. Limitations Of Use • Ozempic Has Not Been Studied In Patients With A History Of Pancreatitis. Consider Other Antidiabetic Therapies In Patients With A History Of Pancreatitis [See Warnings And Precautions ( 5.2 )] . • Ozempic Is Not A Substitute For Insulin. Ozempic Is Not Indicated For Use In Patients With Type 1 Diabetes Mellitus Or For The Treatment Of Patients With Diabetic Ketoacidosis, As It Would Not Be Effective In These Settings. Ozempic Is A Glucagon-Like Peptide 1 (Glp-1) Receptor Agonist Indicated As: • An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus ( 1 ). • To Reduce The Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease ( 1 ). Limitations Of Use: • Has Not Been Studied In Patients With A History Of Pancreatitis. Consider Another Antidiabetic Therapy ( 1 , 5.2 ). • Not Indicated For Use In Type 1 Diabetes Mellitus Or Treatment Of Diabetic Ketoacidosis ( 1 ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Semaglutide

Comments